NCT07075718RecruitingPhase 2
Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- First submitted
- 10 Jul 2025
- Start date
- 12 Jun 2025
- Primary completion date
- 31 Mar 2028
- Lead sponsor
- Glaukos Corporation
- Diseases
- Glaucoma, High blood pressure
- NCT number
- NCT07075718
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 110
- From 12 Jun 2025 to the primary completion date, 31 Mar 2028
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior incisional glaucoma surgery in the study eye
- Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Lab values
- Prior argon laser trabeculoplasty (ALT) in the study eye
Who the study is looking for
- Diagnosis of open-angle glaucoma or ocular hypertension in the study eye
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Glaukos Clinical Site Coordinator of this site? Confirm its status | El Paso | United States | Recruiting |
| Glaukos Investigative Site Coordinator of this site? Confirm its status | Grand Junction | United States | Recruiting |
| Glaukos Investigative Site Coordinator of this site? Confirm its status | Oklahoma City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.